
Tos-Gly-Pro-Arg-ANBA-IPA acetate
CAS No. 2070009-46-8
Tos-Gly-Pro-Arg-ANBA-IPA acetate( tos-GPR-ANBA-IPA acetate )
Catalog No. M29724 CAS No. 2070009-46-8
Tos-Gly-Pro-Arg-ANBA-IPA (acetate) is a peptide substrate for luminescence measurement.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 311 | Get Quote |
![]() ![]() |
10MG | 446 | Get Quote |
![]() ![]() |
50MG | 1337 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameTos-Gly-Pro-Arg-ANBA-IPA acetate
-
NoteResearch use only, not for human use.
-
Brief DescriptionTos-Gly-Pro-Arg-ANBA-IPA (acetate) is a peptide substrate for luminescence measurement.
-
DescriptionTos-Gly-Pro-Arg-ANBA-IPA (acetate) is a peptide substrate for luminescence measurement.
-
In Vitro——
-
In Vivo——
-
Synonymstos-GPR-ANBA-IPA acetate
-
PathwayOthers
-
TargetOther Targets
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2070009-46-8
-
Formula Weight747.82
-
Molecular FormulaC32H45N9O10S
-
Purity>98% (HPLC)
-
SolubilityH2O : ≥ 25 mg/mL (33.43 mM)
-
SMILES——
-
Chemical NameSequence:Tos-Gly-Pro-Arg-ANBA-IPA
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
7-Amino-4-(trifluoro...
7-Amino-4-(trifluoromethyl)coumarin is a 5-Hydroxytryptamine Receptor Subtype 1E (HTR1E) antagonist.
-
Shield-1
Shield-1 is a specific, high-affinity and cell-permeant ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to mutated FKBP (mtFKBP), allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize the entire fusion protein.
-
ZINC77292789
Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a reagent for the preparation of a synthetic MUC1 Glycopeptide Bearing βGalNAc-?Thr as a Tn antigen isomer which induces the antibody production against tumor cells. Fmoc-Thr[GalNAc(Ac)3-α-D]-OH is a starting material to make trimeric MUC1 immunodominant motif antigen-?based anti-?cancer vaccine candidates.